Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways

Journal of Clinical Pathology

Volumn 59, Issue 7, 2006, Pages 685-691

  Schmitz, K J ^a   Callies, R ^a   Wohlschlaeger, J ^a   Kimmig, R ^a   Otterbach, F ^a   Bohr, J ^a   Lee, H S ^a   Takeda, A ^b   Schmid, K W ^a   Baba, H A ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GUNMA PAZ UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B;

ADULT; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

AGED; BREAST NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745905043     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.030650     Document Type: Article

References (43)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 2001;19:3817-27.
3. Khuder SA, Herial NA, Mulgi AB, et al. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 2005;127:748-54.
4. Howe LR, Subbaramaiah K, Brown AM, et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97-114.
5. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-9.
6. Bennett A, Stamford IF, Cooper D. Human cancer prostaglandins and patient survival. Adv Prostagland Thromb Leukotr Res 1991;21B:875-8.
7. Bennett A, Charlier EM, McDonald AM, et al. Prostaglandins and breast cancer. Lancet 1977;2:624-6.
8. Rolland PH, Martin PM, Jacquemier J, et al. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980;64:1061-70.
9. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-60.
10. Brueggemeier RW, Quinn AL, Parrett ML, et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999;140:27-35.
11. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
12. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-87.
13. Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 1999;86:2551-63.
14. Winde G, Schmid KW, Schlegel W, et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995;38:813-30.
15. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7:203-5.
16. Egan KM, Stampfer MJ, Giovannucci E, et al. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996;88:988-93.
17. Wendum D, Masliah J, Trugnan G, et al. Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch 2004;445:327-33.
18. Panigrahi AR, Pinder SE, Chan SY, et al. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 2004;204:93-100.
19. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002;86:540-5.
20. Schmitz KJ, Otterbach F, Callies R, et al. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 2004;17:15-21.
21. St Germain ME, Gagnon V, Mathieu I, et al. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. Int J Oncol 2004;24:1311-24.
22. St Germain ME, Gagnon V, Parent S, et al. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer 2004;3:7.
23. Subbaramaiah K, Chung WJ, Dannenberg AJ. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem 1998;273:32943-9.
24. Gauthier ML, Pickering CR, Miller CJ, et al. p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue. Cancer Res 2005;65:1792-9.
25. Simeone AM, Li YJ, Broemeling LD, et al. Cyclooxygenase-2 is essential for HER2/neu to suppress N-(4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells. Cancer Res 2004;64:1224-8.
26. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopathology 1991;19:403-10.
27. Schmitz KJ, Grabellus F, Callies R, et al. High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Res 2005;7:R194-203.
28. Ellis PS, Whitehead R. Mitosis counting - a need for reappraisal. Hum Pathol 1981;12:3-4.
29. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
30. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004;291:2433-40.
31. Nozoe T, Ezaki T, Kabashima A, et al. Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. Am J Surg 2005;189:110-5.
32. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999;5:2018-24.
33. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
34. Half E, Tang XM, Gwyn K, et al. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-81.
35. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
36. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002;190:279-86.
37. Tang Q, Gonzales M, Inoue H, et al. Roles of Akt and glycogen synthase kinase 3beta in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. Cancer Res 2001;61:4329-32.
38. Leng J, Han C, Demetris AJ, et al. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003;38:756-68.
39. Vadlamudi R, Mandal M, Adam L, et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999;18:305-14.
40. Winde G, Lugering N, Glodny B, et al. Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention. Cancer Lett 1998;134:201-7.
41. Witton CJ, Hawe SJ, Cooke TG, et al. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 2004;45:47-54.
42. Costa C, Soares R, Reis-Filho JS, et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002;55:429-34.
43. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-23.